Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2012; 7(4): e33214.
Published online Apr 2, 2012. doi:  10.1371/journal.pone.0033214
PMCID: PMC3317639

Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells

Lin Zhang, Editor

Abstract

Mesothelin, a differentiation antigen present in a series of malignancies such as mesothelioma, ovarian, lung and pancreatic cancer, has been studied as a marker for diagnosis and a target for immunotherapy. We, however, were interested in evaluating the effects of direct targeting of Mesothelin on the viability of cancer cells as the first step towards developing a novel therapeutic strategy. We report here that gene specific silencing for Mesothelin by distinct methods (siRNA and microRNA) decreased viability of cancer cells from different origins such as mesothelioma (H2373), ovarian cancer (Skov3 and Ovcar-5) and pancreatic cancer (Miapaca2 and Panc-1). Additionally, the invasiveness of cancer cells was also significantly decreased upon such treatment. We then investigated pro-oncogenic signaling characteristics of cells upon mesothelin-silencing which revealed a significant decrease in phospho-ERK1 and PI3K/AKT activity. The molecular mechanism of reduced invasiveness was connected to the reduced expression of β-Catenin, an important marker of EMT (epithelial-mesenchymal transition). Ero1, a protein involved in clearing unfolded proteins and a member of the ER-Stress (endoplasmic reticulum-stress) pathway was also markedly reduced. Furthermore, Mesothelin silencing caused a significant increase in fraction of cancer cells in S-phase. In next step, treatment of ovarian cancer cells (OVca429) with a lentivirus expressing anti-mesothelin microRNA resulted in significant loss of viability, invasiveness, and morphological alterations. Therefore, we propose the inhibition of Mesothelin as a potential novel strategy for targeting human malignancies.

Introduction

Mesothelin (MSLN), a plasma membrane differentiation antigen, is expressed at significantly high levels in several human cancers, including nearly all mesotheliomas [1] and pancreatic adenocarcinomas [2], [3] as wells as about 70% of ovarian cancers [4], [5] and 50% of lung adenocarcinomas [6], [7]. MSLN is detected in over 70% of fine needle aspirates (FNA) of pancreatic adenocarcinomas [2]. Another recent study showed pleural effusion MSLN as a useful marker for detection of malignant pleural mesothelioma [8]. MSLN is also expressed in trace amounts in normal mesothelial cells. MSLN gene encodes a 69-kDa polypeptide containing hydrophobic sequence at the carboxyl end which is removed and replaced by phosphatidylinositol. MSLN gene contains 17 exons on human chromosome 16p13.3 and the MSLN cDNA is 2138-bp long, with an open reading frame of 1884 base pair.

Mutant mice with inactivation of both copies of MSLN gene were generated with the purpose of studying the function of this protein although no detectable abnormalities were reported for this phenotype [9] http://clincancerres.aacrjournals.org/cgi/content/full/10/12/3937 - B8#B8. Another set of studies have introduced MSLN to be involved in adhesion since NIH3T3 cells transfected with a MSLN expression vector were more difficult to remove from the culture dishes than non-transfected cells [1]. The possibility of a role for MSLN in adhesion is supported by a study showing that MSLN binds to CA125(MUC16), a member of the mucin family glycoproteins, and that such interaction mediates cell adhesion [4]. Based on these findings, the authors suggested that there may be an important role for CA125 and MSLN in the metastatic spread of cancer [4]. Also, mesothelin interaction with MUC16 was suggested to facilitate peritoneal metastasis [10].

In models such as ovarian cancer, analyses of correlation between MSLN expression, pathological variability and clinical outcomes indicated that high MSLN expression was positively associated with chemo-resistance in epithelial ovarian carcinoma patients and short patient survival time [12]. MSLN and another marker HE4 have been recently studied for their value as markers for detection of ovarian carcinoma [5], [11]. From other malignancies the homologous to MSLN gene, namely Erc was found to be over-expressed in rat renal carcinoma [12], [13]. In gastric cancer patients, the MSLN positive group had significantly more nodal involvement and significantly deeper tumor invasion than the MSLN negative group [14]. Interestingly, the 5-year survival rate was found to be higher in MSLN positive group in this study.

Several studies have indicated important interactions between signaling pathways involved in development of malignant phenotype and MSLN. For example, MSLN was found to induce expression of matrix metalloproteinases 7 (MMP-7) [15] or to enhance expression levels of interleukin 6 (IL-6) [16]. Expression of mesothelin is also claimed to confer resistance to apoptosis in response to tumor necrosis factor alpha (TNF-alpha) [17]. The MSLN gene is differentially regulated by members of the Wnt signal transduction pathway [18]. Also, in C57MG mouse mammary epithelial cells, MSLN was up-regulated by Wnt-1. Interestingly, tumors with constitutive activation of the Wnt signaling pathway, such as ovarian and pancreatic cancers, have high MSLN expression. Additional studies are needed to fully define MSLN function as well as the role of MSLN in carcinogenesis. The very limited distribution of MSLN on normal tissues portrays MSLN a suitable candidate for tumor-specific therapy. Although strategies such as using monoclonal antibodies targeted against MSLN have been tried before [19], [20], [21], [22], [23], [24], the effect of direct inhibition of MSLN on the viability of cancer cells remains to be investigated. In addition to the translational ramifications of such investigations, the information obtained is useful for evaluating the role of MSLN in cancer biology. In this work, we studied the effects of silencing MSLN on viability, invasiveness and cell signaling pathways in cancer cells derived from mesothelioma, pancreatic and ovarian cancer. Furthermore, silencing MSLN by a lentivirus expressing anti-mesothelin microRNA (miRNA) was also found to significantly reduce the viability and invasiveness of ovarian cancer cells. We have also investigated the outcome of silencing MSLN on cell signaling characteristics of cancer cells and cell cycle progression in order to further understand the pathways involved in the biological role of this antigen.

Materials and Methods

Cell Lines and chemicals

Bxpc3, H2373, Ovcar5, and Skov3 cells (all obtained from the American tissue culture collection, www.atcc.gov other than H2373 which was obtained from national cancer institute, NCI) were cultured in RPMI-1640 medium that was supplemented with 10% fetal bovine serum (FBS) (Sigma, St Louis, MO). Ovcar3 is cultured in RPMI-1640 with 10% FBS with addition of 2 mM L-glutamine and 10 µg/ml insulin. NIH3T3, Panc1, Maipaca2 (from ATCC), and OVca429 cells [25] were cultured in Dulbecco's Modification of Eagle's Medium (DMEM) (Sigma) supplemented with 10% FBS. Huvec cells were cultured in F-12K Medium supplemented with 0.1 mg/ml heparin, 0.05 mg/ml endothelial cell growth supplement, and 10% FBS. HT1080 cells were cultured in MEME supplemented with 10% FBS. The above mediums were supplemented with penicillin (100 IU/ml) and streptomycin (100 mg/ml) (Sigma). 293FT cells were cultured in DMEM (high glucose) supplemented with 10% FBS, 0.1 mM MEM non-essential amino acid, 1 mM L-glutamine, and 1 mM MEM sodium pyruvate. HT1080, NIH3T3, and Huvec cells were purchased from ATCC (Manassas, VA). 297FT cells were purchased from Invitrogen (Carlsbad, CA).

Anti-mesothelin siRNA was ordered from Qiagen (Valencia, CA). It was synthesized in double-stranded format with Alexa Fluor 488(AF488) conjugated to the 3′ end of its sense strand. The siRNA oligo was re-suspended in the provided buffer at final stock concentration of 20 µM.

SiRNA electroporation

107 to 5×107 cells were re-suspended in 270 µl of Opti-MEM and mixed with 30 µl of 20 µM siRNA stock solution and electroporated (~240 V, one pulse for 20 milliseconds), so the final concentration of anti-mesothelin siRNA was 2 µM. The brightest cells, i.e., the cells with the most amount of siRNA, were selected on the basis of the presence of Alexa Fluor 488 tag at the 3′ end of siRNA molecule using FACS.

Cell proliferation assay

Cell proliferation assay was performed using WST-1 kit from Millipore (Billerica, MA) according to the manufacturer's protocol. Briefly, 2,000 cells (sorted by FACS) were plated in each well of a 96-well microplate in a final volume of 100 µl. Then 10 µl/well of WST-1 reagent was added and the plate was incubated for 1 hour in standard culture conditions. During incubation, viable cells convert WST-1 reagent into formazan dye by cellular mitochondrial dehydrogenase. Following this incubation, the absorbance was measured at 440/600 nm.

Cell invasion assay

The matrigel invasion chambers and falcon companion tissue culture plate were obtained from BD Biosciences (San Jose, CA). For siRNA experiments control and anti-mesothelin siRNA-treated cells (30,000 cells/well) were plated in 24-well plate and incubated at 37°C with 5% CO2. Forty-eight hours later, the cells were fixed in 100% methanol and stained in 0.05% crystal violet and photographed to visually count the number of invaded cells. For lentivirus related experiments cells were pre-treated with lentivirus for 3 days and then introduced to the Boyden chamber assay for ~21 hrs.

Western blot analysis

Cells were lysed at 5, 24, and 48 hours post-electroporation with 1× cell lysis buffer. Thirty microgram of proteins for each sample was loaded onto 4–20% SDS polyacrylamide gel (Bio-Rad, CA). Proteins were then transferred onto a nitrocellulose membrane. The membrane was blocked, washed, and incubated with the different primary antibodies such as mesothelin (Abcam, MA and LS Bio, WA) and β-actin (Cell Signaling Technology, MA), followed by the HRP-conjugated secondary antibody. After a thorough washing, the blot was exposed to ECL (GE Healthcare, NJ) and autoradiography.

Cell cycle assay

Cell cycle assay was performed according to manufacturer's instructions. Briefly, about 106 cells were washed twice using CycleTEST PLUS Buffer solution (BD Biosciences, Cat. 340242). Cells were re-suspended in 1 ml of the same buffer. To stain the cells, 250 µl of Solution A and 200 µl Solution B were added and incubated for 10 minutes at RT. Cold Solution C (200 µl) was added and incubated at 4°C for 10 minutes. The cells were filtered through a 35 µm cell strainer and analyzed by FACSort flow cytometer.

Construction of vector expressing miRNA

We designed and synthesized three miRNA mimics targeting the full length of human mesothelin gene (gene access number: NM_005823.4). Each designed miRNA mimic was 64 nucleotides in length, including partial flanking sequence, the miRNA hairpin, and mature miRNA (italicized/underlined) derived from target gene as follows: 1-TGCTGATAGCAGCAGGTCCAATGGGAGTTTTGGCCACTGACTGACTCCCATT GCCTGCTGCTAT; 2-TGCTGTTCATGTTCTGGAAAGCAAGGGTTTTGGCCACTGACTGACCCTTGCT TCAGAACATGAA; and 3-TGCTGTTTACTGAGCGCGAGTTCTCTGTTTTGGCCACTGACTGACAGAGA ACTCGCTCAGTAAA.

Using the BLOCK-iT Pol II miR RNAi expression vector kit (Invitrogen, CA), we annealed and cloned the oligos encoding the engineered pre-miRNA into the cloning site (ACGA and CAGG) of pcDNA 6.2-GW/EmGFP-miR vectors that is flanked on either side to allow directional cloning or proper process of pre-miRNA. The pre-miRNA was inserted into the 3′-UTR of EmGFP gene-driven by Pol II promoters. EmGFP allows tracking expression of the miRNA, providing a strong correlation between EmGFP and miRNA expression. Each plasmid was sequenced to confirm the inserted double stranded miRNA oligos. The expressing plasmids were electroporated into Ovcar5 cells or Skov3 cells, and analyzed by FACS to ensure the proper expression of miRNA in ovarian cancer cells.

Generation of lentiviral particles expressing miRNA

The entry clone was generated by combining pMSLNmiR3 with pDONR 221 construct using BP Clonase II enzyme. The miRNA cassette was transferred into the pLenti6.3/TO/V5-DEST vector containing attR1-attR2 sites using LR Clonase II to create the final lentiviral vector MSLNmiR3. In addition, we created a lentiviral vector encoding scrambled miRNA (Negative Control) (TGCTGAAATGTACTGCGCGTGGAGACCTTTTGGCCACTGACTGACGTCTCCAC GCGCAGTACATTT) (Invitrogen) that does not target any known human gene. The expression of miRNA is driven by CMV promoter. The inserted sequences of miR3 and scrambled miRNA were confirmed by sequence analysis.

Production, titration and infection of lentiviral particles

The MSLNmiR3 or Negative Control lentivirus was transfected with ViraPower packing mix (Invitrogen, CA) into human 293FT cells using Lipofectamine 2000 in Opti-MEM I medium (Invitrogen, CA) and cultured overnight. The cells were placed under blasticidin (10 µg/ml) selection for 72 hours. The supernatant was collected and lentiviral particles were concentrated using Lenti-X Concentrator (Clontech, CA). Lentiviral stock was diluted in ten-fold serial to infect the HT1080 cells. Forty-eight hours post-infection, the cells were assessed by FACS and the titration was calculated using the formula [FxC/V]xD, where “F” is the frequency of GFP-positive cells; “C” is the total number of cells in the well at the time of transduction; “V” is the volume of inoculums in mL; and “D” is lentivirus dilution. Ovca429 cells were infected with lentivirus particles at MOI~30 in the presence of polybrene (10 µg/ml) overnight. The cell proliferation assay was performed post-infection at the indicated time points.

Flow cytometry

Cultured cells were dissociated with cell dissociation buffer (Sigma-Aldrich, MO) and washed twice in MACS buffer (PBS plus EDTA and 0.5% bovine serum albumin) (Miltenyi Biotec, CA). A total of 2×105 cells (100 µl) were incubated with mesothelin monoclonal antibody (final concentration, 1 µg/ml) (Cat#ab3362, Abcam, MA) on ice for 1 hour in the darkness. Cells were then washed twice with MACS buffer, re-suspended in 100 µl of a secondary antibody (1[ratio]200 dilution, APC conjugated IgG; BD Biosciences, NJ), and incubated on ice for 1 hour in the darkness. Cells were washed twice and analyzed on LSRII analyzer (BD Biosciences, NJ) using the software FACS Diva version 6.1. Cells stained with secondary antibody alone were included to prove the specificity of antibody.

Results and Discussion

We decided to evaluate the effects of silencing MSLN by using short-interfering RNA (siRNA). Mechanistically, these 19–21 oligomers can bind to a specific matching sequence in their target messenger RNAs (mRNAs) and flag them for destruction by a complex referred to as RNA-induced silencing complex (RISC). To achieve this, the sequence of MSLN mRNA was analyzed with specialized software (Qiagen, CA) and sequences for siRNA oligomers were detected. One of these sequences (5′-CTGGACGTCCTAAAGCATAAA-3′) was selected because of its higher degree of specificity against MSLN. The anti-MSLN siRNA oligomer was synthesized (in double-stranded format) and conjugated to Alexa Fluor 488 at the 3′-end of its sense strand (Qiagen, CA). Figure 1A shows the mRNA sequence for human MSLN and the binding site for anti-MSLN siRNA.

Figure 1
Gene specific silencing of mesothelin reduces proliferation of mesothelioma cells.

In order to investigate the effects of anti-MSLN siRNA on the expression of MSLN, we used the H2373 human mesothelioma cell line. As shown in figure 1B, once electroporated with the anti-MSLN siRNA, the expression of MSLN was notably reduced as early as 24–48 hours post-electroporation as compared with the negative control treated cells. No changes were observed in the expression of β-actin (a house-keeping gene product) after exposure of cells to the anti-MSLN siRNA (figure 1C).

We then decided to test the proliferation rate of cancer cells in such conditions. As is seen in figure 1D, a significant reduction (p<0.005) in the proliferation of mesothelioma cells was observed as early as 48 hours post-electroporation. It is important to note that proliferation rate of control siRNA-treated cells at each time-point was measured and then scaled as 100%. The proliferation rate of anti-MSLN siRNA treated cells was calculated and scaled as a fraction of the control values. The callout panels represent the cell density of the test and control treated populations at indicated times post-electroporation. Interestingly the proliferation rate of siRNA-treated cells started to increase at 72–96 hours post-electroporation. This is due to the transient nature of transfection by electroporation which is the method used in these experiments to introduce anti-MSLN siRNA to cells. In other words, as the time passes, the concentration of siRNA in treated cells would diminish allowing a rebound of proliferation. We have observed such phenomenon in our other studies involving gene specific silencing [26], [27]. Once the same procedure was applied to NIH3T3 cells (void of MSLN), no statistically significant changes in the viability was observed (the siRNA used in this experiment can bind to mouse MSLN mRNA) (figure 1E).

In next step, we decided to test the effects of silencing MSLN in other MSLN-expressing cells including ovarian and pancreatic cancer cell lines and compare such effects with our data about mesothelioma cells. The levels of expression of MSLN in a panel of pancreatic and ovarian cancer cells were tested using western blotting as shown in figure 2A. Miapaca2, BxpC3 and Panc1 (pancreatic cancer cell lines) and Skov3 and Ovcar3 (ovarian cancer cell lines) showed increased levels of MSLN expression while Huvec (Human umbilical vein endothelial cells) and NIH3T3 cells remained negative for MSLN as expected. Electroporation of all above mentioned cancer cell lines resulted in a significant reduction in their viability (figure 2B–2D, results shown for Skov3, BxPC3 and MiapaCa2). Once again a rebound of proliferation due to clearance of siRNA from pancreatic and ovarian cancer cells was observed. The time frame for this rebound was variable among these cell lines due to their relative clearance rate of siRNA.

Figure 2
Mesothelin silencing reduces proliferation rate of pancreatic and ovarian cancer cells.

While all cancer cells showed significant loss of viability upon electroporation with anti-MSLN siRNA, cells with no expression of MSLN such as NIH3T3 did not exhibit significant changes in their proliferation rates once electroporated with anti-MSLN siRNA (targeting mouse MSLN). Therefore, normal cells, with very low or no expression of MSLN would not be affected by this strategy implying the specificity of the biological outcomes of MSLN silencing for malignant cells. Therefore inhibition of MSLN can be considered as a potential strategy for targeting tumors such as mesothelioma, ovarian and pancreatic cancer in a cell specific manner. Recent clinical trials using monoclonal antibodies against MSLN have also been reported to be well-tolerated in patients confirming minimal in-vivo side effects for MSLN targeting strategies [28], [29]. This is of special importance due to the limited levels of mesothelin expression in pleural, pericardial, and peritoneal membranes [30], [31].

We were also interested in investigating the corollary of silencing MSLN on the invasiveness of cancer cells. Metastasis as the most devastating outcome of malignancies plays an important role in the pathogenesis of cancer. Therefore, it is a logical step to study the outcome of silencing mesothelin on the capabilities of cancer cells to invade. This is also an important concern considering the invasive nature of malignancies studied in this work. For such purpose we used an in-vitro model based on studying the capabilities of cells to invade through a layer of matrigel as a model for metastasis (modified Boyden chamber assay). We evaluated the invasiveness of H2373, Skov3 and BxPC3 cells once treated with anti-MSLN and control siRNA (figure 3A–3C). In all three cases a significant reduction in invasiveness was observed. The decreased invasiveness of all tested cancer cells is of special clinical relevance due to the high metastatic nature of these diseases.

Figure 3
The effects of silencing mesothelin on cancer cell invasiveness, pro-oncogenic cell signaling pathways and cell cycle progression.

To this end, we had observed the loss of viability and invasiveness in a range of cancer cells upon silencing of MSLN. In order to somewhat elucidate the molecular mechanism underlying such phenotypic changes we evaluated the activation/expression level of some of the most important signaling proteins involved in neoplastic transformation in H2373 cells (figure 3D). Effector pathways down-stream of proto-oncogene Ras [32], [33], [34] such as activation of ERK1/2 (extracellular signal-related kinase), phosphatidylinositol 3-kinase (PI3K/AKT) and p38 (p38-kinase) were studied for this purpose. We observed that upon MSLN silencing, phospho-ERK1 and phospho-AKT activation levels were profoundly decreased while the levels of phospho-p38 remained unchanged (figure 3D). With involvement of ERK in proliferation and metastasis [35], [36] and also involvement of PI3K/AKT pathway in protection against apoptosis [37], a decrease in the activation of these signaling pathways can explain the anti-proliferative effects of silencing MSLN. However, p38-pathway [38] (involved in stress signaling, apoptosis and senescence) seemed to remain unaltered upon inhibition of MSLN. Since p38-kinase acts as a growth inhibitory pathway, it is conceivable that the capacity of cells to undergo growth inhibition and/or apoptosis (dictated by p38-kinase pathway) remains unaffected by silencing MSLN.

The outcome of siRNA-mediated knockdown of MSLN on epithelial-mesenchymal transition (EMT) [39], [40], a biological program for enhancement of metastatic capabilities, was also investigated by our team. EMT is an important biological step towards achievement of a metastatic phenotype by cancer cells [41]. Beta-Catenin, one of Wnt down-stream signaling molecules and also an important player in EMT, was found to be significantly reduced upon silencing MSLN (figure 3D, the middle panel). Slug, another transcriptional repressor involved in EMT was found to be somewhat increased upon MSLN silencing [42]. With considerations to the role of Slug in repression of E-Cadherin [43] it would be a logical next step to evaluate the expression levels of E-Cadherin upon mesothelin silencing. However, no meaningful change was observed in the levels of E-Cadherin (data not shown). Therefore the incremental increase in the levels of this protein may not positively affect the EMT capabilities of cancer cells once mesothelin is silenced.

We were also interested to investigate the levels of expression of markers involved in the regulation of ER-stress. Stress situations interrupting ER function lead to accumulation of unfolded proteins in the ER which is referred to as ER-Stress [44], [45]. Upon such conditions an integrated panel of signaling pathways becomes activated resulting in the unfolded protein response (UPR) [46], [47]. Following continuation of the UPR response and if the unfolded proteins are not cleared mechanism will be activated to induce cell death. Existence of chronic ER-Stress conditions is becoming increasingly evident in cancer cells [47]. Therefore it would be novel and interesting to see if changes in ER-Stress pathway would contribute to the outcome of MSLN silencing in cancer cells.

ER-residing protein endoplasmic oxidoreductin-1 (Ero1), one of the molecules involves in ER-stress pathway, oxidizes protein disulfide isomerase (PDI), which, in turn, introduces disulfide bands to ER proteins [48]. The significant decrease observed in Ero1 upon MSLN silencing might result in a decreased capacity of cancer cells to fold and clear proteins leading to their eventual death (Figure 3D, lower panel). Also, an increased expression was observed in Bip (Luminal binding protein precursor), a molecular chaperon involved in preventing protein aggregation [49]. Such observation might be indicative of elevated levels of protein unfolding upon MSLN silencing as Bip levels are usually raised in the cell to combat aggregation of unfolded proteins [50].

The last phenotypical feature studied in MSLN-silenced cells was the progression of cell cycle. The major change observed in these cells was a significant increase (~50%) in the fraction of cells in S-phase portraying a blockade in progression from S to G2 phase (figure 3E).

The current approach for advancing inhibitory RNA therapy to pre-clinical and clinical studies mainly relies on using lentiviruses in order to express and deliver siRNA molecules in a continuous manner [51], [52], [53]. For such purpose, and to produce a translational tool for targeting cancer cells on the basis of inhibition of MSLN, we decided to develop a lentivirus expressing anti-MSLN miRNA. Such tool can be used in future to further evaluate the pre-clinical value of MSLN gene specific silencing as a therapeutic approach.

As short ribonucleic acid (RNA) molecules (~22 nucleotides) found in all eukaryotic cells, miRNAs are post-transcriptional regulators which bind to complementary sequences on target mRNA transcripts. This results in translational repression and gene specific silencing [54], [55]. Once a series of three miRNA sequences (miR1, miR2 and miR3, relative positions are shown in figure 4A, upper panel) were selected, each of them was cloned into an expression plasmid (pcDNA6.2-GW/EmGFP, Invitrogen) and electroporated into Ovcar5 cells. All plasmids were efficiently electroporated into the cells (based on GFP expression) (figure 4A, middle panel). Two of the designed miRNAs (miR1 and miR3) out of three silenced MSLN efficiently as was revealed by western blotting (figure 4A, lower panel). Further, miR3 was selected to develop the anti-MSLN lentivirus (named MSLNmiR3). The structure of the MSLNmiR3 lentivirus is shown in figure 4B (upper panel). Ovarian cancer cell line Ovca429 cells, with high levels of MSLN expression, were infected by MSLNmiR3 and its negative control counterpart (encoding scrambled sequence) at MOI~30. The percentage of MSLN-expressing cells were reduced from ~77% in cells treated with the negative control virus to 18% in cells treated with MSLNmiR3 (figure 4B, middle panel). For both viruses, the viral entrance was almost equal as was proven by EmGFP expression (figure 4B, lower panel).

Figure 4
MiRs suppress MSLN expression in human ovarian cancer cells.

In next step, we evaluated the viability of ovarian cancer cells once treated with this virus. The viability of Ovca429 cells upon infection with MSLNmiR3 (MOI~30) showed about 15% decreases at day-6 post-infection and about 50%, 60% reduction at day-16 and day-22, respectively (figure 5A). This is achieved by treatment with a single dose of the virus. Figure 5B shows the morphology of cells treated with MSLNmiR3 or the negative control virus at day-16 (20× objectives) and day-6 (10× objectives). An interesting phenomenon was the enlargement of remaining cells upon exposure to MSLNmiR3 lentivirus. This might entail a role for MSLN in machinery involved in the cell morphology, polarity and cytoskeletal reorganization which influences invasiveness of cancer cells although the field needs more studies in this regards [41], [56], [57]. Additionally, the resemblance in the biological outcome of silencing mesothelin by two distinct agents, siRNA and miRNA, reduces the possibility of off-target events and involvement of any player other than MSLN in this scenario. Also, the rate of loss of viability upon targeting cancer cells with anti-mesothelin lentivirus is notably slower as compared to silencing mesothelin by siRNA electroporation. This is due to the kinetics of the expression of miRNA from the context of lentiviral genome which happens at a much slower rate in comparison to the rapid influx of siRNA to cytoplasm achieved by siRNA electroporation.

Figure 5
Silencing MSLN confers inhibited cell proliferation and invasion.

Finally, direct study of cell invasiveness in a modified Boyden chamber assay also showed a close to 40% reduction in the metastatic capability of Ovca429 cells at day-2 post-infection. Such information reveals a significant role for mesothelin in influencing the metastatic capability of cancer cells. The work, therefore, provides clues to the mechanisms involved in the role of MSLN in cancer cell's proliferative capabilities, invasion (through EMT marker changes), ER-Stress signaling and phenotypical changes.

Conclusion and Future Directions

The biological function of MSLN is not well-understood. This study delineates functional role of MSLN in cancer cell survival and possible signaling pathways that may confer MSLN action in a number of distinct malignancies. This is indeed of significant importance because cancer models pursued in this report (mesothelioma, pancreatic and ovarian cancers) seem to collectively follow the outcome of elimination of MSLN as a biological turn-point.

It is also important to take notice of the level “cancer cell addiction” to the expression of this differentiation antigen for the proper maintenance of its biological functions. Our data in all studied cancer models show that a significant loss of viability follows the loss of MSLN expression. In light of this, MSLN can be rendered as suitable candidate for drug therapy with focus on finding novel small molecule inhibitors which can bind and inhibit MSLN. Our data in regards to cell signaling changes upon MSLN silencing are useful for developing evaluation assays for studying biochemical function of such anti-MSLN compounds. Once such compounds with inhibitory function against MSLN are available, their effect on the relationship between MSLN and CA125 can be studied. Our team is involved in such drug discovery efforts as well and has found a few compounds with enhanced cytotoxicity against MSLN expressing cancer cells (unpublished data).

The other tool provided in our work, the anti-MSLN lentivirus (MSLNmiR3), can also serve as a translational tool for the gene therapy of MSLN expressing tumors. Animal experiments are under way for evaluating the efficiency of this virus in causing tumor regression in-vivo. Altogether, our findings revealed MSLN as a potential target for achieving better understanding of the biology of a number of human malignancies as well as designing novel therapeutic strategies for cancer therapy.

Acknowledgments

This work is dedicated to the loving memory of “Brady Stanton” and “Nancy Lopez” and their loved ones for their courageous battle against cancer.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: Research at F. Farassati's laboratory is supported by “All in For Cure”, “Mesothelioma Applied Research Foundation (MARF)”, “Marsha Rivkin Institute for Ovarian Cancer (MRC)” and “Flight attendant Medical Research Institute (FAMRI)”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996;93:136–140. [PMC free article] [PubMed]
2. Glass JP, Parasher G, Arias-Pulido H, Donohue R, Cerilli LA. Mesothelin and GPR30 Staining Among a Spectrum of Pancreatic Epithelial Neoplasms. Int J Surg Pathol 2011 [PubMed]
3. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-Ong GL, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003;63:8614–8622. [PubMed]
4. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279:9190–9198. [PubMed]
5. Hellstrom I, Hellstrom KE. fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. Expert Opin Med Diagn. 2011;5:227–240. [PMC free article] [PubMed]
6. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, et al. Mesothelin expression in human lung cancer. Clin Cancer Res. 2007;13:1571–1575. [PubMed]
7. Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, et al. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther. 2002;1:595–600. [PubMed]
8. Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 2011 [PubMed]
9. Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol. 2000;20:2902–2906. [PMC free article] [PubMed]
10. Gubbels JA, Belisle J, Onda M, Rancourt C, Migneault M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006;5:50. [PMC free article] [PubMed]
11. Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pac J Cancer Prev. 2010;11:111–116. [PubMed]
12. Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun. 2000;275:134–140. [PubMed]
13. Mak BC, Takemaru K, Kenerson HL, Moon RT, Yeung RS. The tuberin-hamartin complex negatively regulates beta-catenin signaling activity. J Biol Chem. 2003;278:5947–5951. [PubMed]
14. Baba K, Ishigami S, Arigami T, Uenosono Y, Okumura H, et al. Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol. 2012;105:195–199. [PubMed]
15. Chang MC, Chen CA, Chen PJ, Chiang YC, Chen YL, et al. Mesothelin Enhances Invasion of Ovarian Cancer by Inducing MMP-7 through MAPK/ERK and JNK Pathways. Biochem J 2011 [PubMed]
16. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis. 2011;32:1013–1024. [PMC free article] [PubMed]
17. Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-alpha-induced apoptosis through Akt/PI3K/NF-kappaB activation and IL-6/Mcl-1 overexpression. Mol Cancer. 2011;10:106. [PMC free article] [PubMed]
18. Prieve MG, Moon RT. Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57 mg mouse mammary epithelial cells. BMC Dev Biol. 2003;3:2. [PMC free article] [PubMed]
19. Breidenbach M, Rein DT, Everts M, Glasgow JN, Wang M, et al. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther. 2005;12:187–193. [PubMed]
20. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13:5144–5149. [PubMed]
21. Hassan R, Lerner MR, Benbrook D, Lightfoot SA, Brackett DJ, et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res. 2002;8:3520–3526. [PubMed]
22. Hassan R, Viner JL, Wang QC, Margulies I, Kreitman RJ, et al. Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J Immunother (1997) 2000;23:473–479. [PubMed]
23. Hassan R, Williams-Gould J, Steinberg SM, Liewehr DJ, Yokokawa J, et al. Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts. Clin Cancer Res. 2006;12:4983–4988. [PubMed]
24. Hassan R, Wu C, Brechbiel MW, Margulies I, Kreitman RJ, et al. 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int J Cancer. 1999;80:559–563. [PubMed]
25. Karlan BY, Amin W, Band V, Zurawski VR, Jr, Littlefield BA. Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. Gynecol Oncol. 1988;31:103–112. [PubMed]
26. Bodempudi V, Yamoutpoor F, Pan W, Dudek AZ, Esfandyari T, et al. Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol. 2009;29:3964–3974. [PMC free article] [PubMed]
27. Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, et al. Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther. 2008;7:3586–3597. [PMC free article] [PubMed]
28. Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010;16:6132–6138. [PMC free article] [PubMed]
29. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009;15:5274–5279. [PMC free article] [PubMed]
30. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992;50:373–381. [PubMed]
31. Muminova ZE, Strong TV, Shaw DR. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer. 2004;4:19. [PMC free article] [PubMed]
32. Alvarado Y, Giles FJ. Ras as a therapeutic target in hematologic malignancies. Expert Opin Emerg Drugs. 2007;12:271–284. [PubMed]
33. Scharovsky OG, Rozados VR, Gervasoni SI, Matar P. Inhibition of ras oncogene: a novel approach to antineoplastic therapy. J Biomed Sci. 2000;7:292–298. [PubMed]
34. Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H, et al. Signaling through RAS-RAF-MEK-ERK: from basics to bedside. Curr Med Chem. 2007;14:601–623. [PubMed]
35. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 2002;25:511–518. [PubMed]
36. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–3310. [PubMed]
37. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17:590–603. [PubMed]
38. Debacq-Chainiaux F, Boilan E, Dedessus Le Moutier J, Weemaels G, Toussaint O. p38(MAPK) in the senescence of human and murine fibroblasts. Adv Exp Med Biol. 2010;694:126–137. [PubMed]
39. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–4751. [PMC free article] [PubMed]
40. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117–134. [PMC free article] [PubMed]
41. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15–33. [PubMed]
42. Alves CC, Carneiro F, Hoefler H, Becker KF. Role of the epithelial-mesenchymal transition regulator Slug in primary human cancers. Front Biosci. 2009;14:3035–3050. [PubMed]
43. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003;116:499–511. [PubMed]
44. Banhegyi G, Baumeister P, Benedetti A, Dong D, Fu Y, et al. Endoplasmic reticulum stress. Ann N Y Acad Sci. 2007;1113:58–71. [PubMed]
45. Boelens J, Lust S, Offner F, Bracke ME, Vanhoecke BW. Review. The endoplasmic reticulum: a target for new anticancer drugs. In Vivo. 2007;21:215–226. [PubMed]
46. Koumenis C. ER stress, hypoxia tolerance and tumor progression. Curr Mol Med. 2006;6:55–69. [PubMed]
47. Lee AS, Hendershot LM. ER stress and cancer. Cancer Biol Ther. 2006;5:721–722. [PubMed]
48. Araki K, Nagata K. Functional in vitro analysis of ERO1 and protein-disulfide isomerase (PDI) pathway. J Biol Chem 2011 [PMC free article] [PubMed]
49. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett. 2007;581:3641–3651. [PMC free article] [PubMed]
50. Kohno K, Normington K, Sambrook J, Gething MJ, Mori K. The promoter region of the yeast KAR2 (BiP) gene contains a regulatory domain that responds to the presence of unfolded proteins in the endoplasmic reticulum. Mol Cell Biol. 1993;13:877–890. [PMC free article] [PubMed]
51. Rovira C, Guida MC, Cayota A. MicroRNAs and other small silencing RNAs in cancer. IUBMB Life. 2010;62:859–868. [PubMed]
52. Couto LB, High KA. Viral vector-mediated RNA interference. Curr Opin Pharmacol. 2010;10:534–542. [PubMed]
53. Hokaiwado N, Takeshita F, Banas A, Ochiya T. RNAi-based drug discovery and its application to therapeutics. IDrugs. 2008;11:274–278. [PubMed]
54. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009;136:642–655. [PMC free article] [PubMed]
55. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233. [PMC free article] [PubMed]
56. Quintela-Fandino M, Gonzalez-Martin A, Colomer R. Targeting cytoskeleton reorganisation as antimetastatic treatment. Clin Transl Oncol. 2010;12:662–669. [PubMed]
57. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev. 2009;28:5–14. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...